Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 3/20 | 0.59 |
| ▸ | HTR1B | P28222 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 10/20 | 0.53 |
| ▸ | DRD3 | P35462 | 9/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336717 | 0.86 | DRD2 (0.70) | HTR1DHTR1BDRD2DRD3DRD4 | |
| SCHEMBL9295705 | 0.78 | DRD2 (0.59) | HTR1DHTR1BDRD2DRD3DRD4 | |
| SCHEMBL23306037 | 0.77 | DRD2 (0.45) | HTR1DHTR1BDRD2DRD3DRD4 | |
| SCHEMBL2787004 | 0.77 | DRD2 (0.45) | HTR1DHTR1BDRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL7399997 | 0.77 | DRD2 (0.58) | HTR1DHTR1BDRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL7399996 | 0.77 | DRD2 (0.58) | HTR1DHTR1BDRD2DRD3DRD4 | |
| SCHEMBL1724881 | 0.75 | GRIN2B (0.71) | HTR1DHTR1BDRD2DRD3GRIN2B | |
| SCHEMBL5221080 | 0.75 | DRD3 (0.43) | HTR1DHTR1BDRD2DRD3DRD4 | |
| SCHEMBL4106723 | 0.74 | HTR1D (0.70) | HTR1DHTR1BDRD2DRD3DRD4 | |
| SCHEMBL8885776 | 0.74 | HTR1D (1.00) | HTR1DHTR1BDRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902191-B2 | Histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20070155754-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | disclosed |
| EP-1720861-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082893-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155754-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | HTR1D 82/4885HTR1B 86/4885DRD2 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.